Product image of Letrozole Sanoswiss (Letrozole) supplied by GNH India

Letrozole Sanoswiss

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Sanoswiss (Letrozole)

Letrozole, the active ingredient in Letrozole Sanoswiss, is an aromatase inhibitor presented as a tablet for oral use. It works by reversibly inhibiting the aromatase enzyme, decreasing peripheral conversion of androgens to estrogens. This reduction in estrogen levels is essential for managing hormone receptor‑positive breast cancer in postmenopausal women, where estrogen can drive tumor proliferation. The drug is approved in the European Union and is incorporated into endocrine therapy regimens.

GNH India supplies Letrozole Sanoswiss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Uab Sanoswiss

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is used in endocrine therapy for hormone‑dependent breast cancer.

  • Hormone receptor‑positive early‑stage breast cancer (postmenopausal): reduces risk of recurrence by lowering estrogen stimulation of residual tumor cells.
  • Hormone receptor‑positive metastatic breast cancer (postmenopausal): slows disease progression through sustained estrogen suppression.
  • Adjuvant therapy after surgery for postmenopausal breast cancer: improves disease‑free survival by maintaining low estrogen levels.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme (CYP19A1) in peripheral tissues, blocking the conversion of androstenedione and testosterone into estrone and estradiol. By inhibiting this key step in estrogen biosynthesis, systemic estrogen concentrations fall markedly, depriving estrogen‑dependent tumor cells of a growth signal. The reduction in circulating estrogen underlies its therapeutic effect in postmenopausal breast cancer.

Side Effects

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Hot flashes: transient episodes of increased skin temperature and sweating.
  • Joint and muscle pain: arthralgia or myalgia affecting mobility.
  • Fatigue: persistent tiredness not relieved by rest.
  • Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

  • Osteoporosis or bone fracture: decreased bone mineral density leading to fractures.
  • Severe liver injury: marked elevation of transaminases or hepatic failure.
  • Cardiovascular events: thrombosis or myocardial infarction.

Precautions & Warnings

When prescribing Letrozole, clinicians should consider several safety and handling precautions.

  • Assess bone health: evaluate baseline bone mineral density and consider calcium/vitamin D supplementation.
  • Monitor liver function: perform periodic liver enzyme tests during therapy.
  • Evaluate cardiovascular risk: screen for hypertension, hyperlipidemia, and prior thrombotic events.
  • Avoid use in premenopausal women: drug is ineffective unless ovarian suppression is achieved.
  • Review drug interactions: check concomitant medications that may affect estrogen levels.
  • Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Avoid Interactions

Letrozole can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole plasma concentrations.
  • Estrogen‑containing hormone therapy (e.g., conjugated estrogens, oral contraceptives): counteracts the intended estrogen suppression.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole, itraconazole): may increase letrozole levels, requiring monitoring for toxicity.
  • Tamoxifen: combined use may affect hormonal balance and should be evaluated by the oncologist.
  • Warfarin: letrozole may enhance anticoagulant effect; monitor INR closely.

Frequently Asked Questions

Letrozole Sanoswiss contains the aromatase inhibitor letrozole and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used as part of endocrine therapy in early‑stage, adjuvant, and metastatic settings to reduce estrogen‑driven tumor growth.

Letrozole blocks the aromatase enzyme (CYP19A1), which converts androgens into estrogens in peripheral tissues. By inhibiting this conversion, circulating estrogen levels fall, depriving estrogen‑dependent breast cancer cells of a key growth stimulus and thereby slowing tumor progression.

The appropriate dose of Letrozole Sanoswiss is determined by the prescribing oncologist or qualified healthcare professional based on the patient’s clinical condition, treatment setting, and individual response. No fixed dosing regimen is provided here; the prescriber sets the regimen according to approved guidelines.

Letrozole is classified as contraindicated in pregnancy because it can interfere with fetal hormone development. It is also not recommended during breastfeeding, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception while on therapy.

To place an order, submit an enquiry on the Letrozole Sanoswiss product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Letrozole is a third‑generation aromatase inhibitor with a high potency and a long half‑life, offering consistent estrogen suppression. Compared with anastrozole or exemestane, letrozole often provides slightly greater reductions in estrogen levels, which can translate into marginally improved disease‑free survival in some clinical trials, though individual response varies.

Letrozole Sanoswiss should be stored at ambient temperature, below 25 °C (77 °F). Keep the tablets in the original container, protect them from moisture, light and excessive heat, and ensure the packaging remains tightly closed until use.

Letrozole Sanoswiss is taken orally, usually once daily, with or without food, as directed by the treating physician. The tablet should be swallowed whole with water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events linked to letrozole include severe osteoporosis leading to fractures, significant liver injury, and rare cardiovascular complications such as thrombosis or myocardial infarction. Patients should be monitored regularly for bone health, liver function and cardiovascular status throughout treatment.

Letrozole is contraindicated in premenopausal women who have not undergone ovarian suppression, in patients with known hypersensitivity to letrozole or any component of the formulation, and in pregnant or breastfeeding women. Caution is also advised for individuals with uncontrolled cardiovascular disease, severe liver impairment, or active bone disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT